Strategic highlights from the presentation of Pharming Group N.V.‘s preliminary (unaudited) financial report for the first six months of 2022 ended 30 June 2022:
- During the first half of 2022, we continued to execute on our strategic objectives of building a sustainable business by focusing on RUCONEST® sales, the approval, launch and commercialization of leniolisib, and the ongoing development and management of our pipeline.
- The development of our pipeline will be through a combination of internal development projects – including the development of additional indications for leniolisib and OTL-105 as a gene therapy for HAE – and the potential acquisition of new, late-stage assets through in-licensing and M&A opportunities.
In July 2021, Pharming announced a strategic collaboration with Orchard Therapeutics to research, develop, manufacture and commercialize OTL-105, a newly disclosed investigational ex vivo autologous hematopoietic stem cell (HSC) gene therapy for the treatment of HAE. The program has made significant progress developing the lentiviral vector to enhance C1-inhibitor expression and is now testing in preclinical HAE disease models. We anticipate providing further updates as we move towards preparing an Investigational New Drug (IND) filing.
(Source: Pharming)
